2020 December 03, 2020 Memo Therapeutics AG’s antibody against SARS-CoV-2 demonstrates potent therapeutic and prophylactic activity in advanced COVID-19 disease model November 18, 2020 Frost & Sullivan Innovation Award goes to Wenzel's exaCT L November 18, 2020 EffRx Pharmaceuticals signs exclusive license agreement with Dipharma SA and launches Miglustat Dipharma in Switzerland November 06, 2020 Memo Therapeutics AG raises CHF 14 million in a series B financing round November 05, 2020 ERS electronic will be presenting its new automatic panel debonding technology at China's largest technical conference for semiconductor packaging technologies October 21, 2020 EffRx Pharmaceuticals signs exclusive license agreement with Diurnal for the registration and commercialization of Alkindi® and submits market authorization application in Switzerland August 25, 2020 EnOcean named 2020 NFC Forum innovation award finalist August 11, 2020 Memo Therapeutics AG and Northway Biotechpharma collaborate on the fast-track manufacturing of a SARS-CoV-2-neutralizing antibody for the therapy of COVID-19 August 10, 2020 Pieris and Lilly enter into a clinical trial collaboration to evaluate combination of PRS-343 with ramucirumab and paclitaxel in gastric cancer July 31, 2020 Ascletis Pharma announces approval for marketing all-oral HCV treatment July 31, 2020 IBM Cloud for Financial Services: Knowis joins ecosystem July 08, 2020 Aruba joins EnOcean Alliance June 04, 2020 Memo Therapeutics AG identifies potent SARS-CoV-2-neutralizing antibodies from the blood of recovered COVID-19 patients April 02, 2020 2020 Sobera Capital acquires three French assets from A Plus Finance March 18, 2020 Memo Therapeutics AG has started the discovery of SARS-CoV2-neutralizing antibodies from COVID-19 patients who have recovered from the infection
